SCHEDULE: Vanguard Reports 0% Coherus Oncology Stake Post-Realignment

The Vanguard Group reports 0% beneficial ownership of Coherus Oncology Inc. common stock following an internal corporate realignment.

Summary

• The Vanguard Group filed an Amendment No. 5 to Schedule 13G for Coherus Oncology Inc. common stock.
• The filing indicates that The Vanguard Group now beneficially owns 0% of Coherus Oncology Inc.'s common stock.
• This change is a result of an internal realignment within The Vanguard Group, Inc. that occurred on January 12, 2026.
• Following the realignment, certain subsidiaries or business divisions of Vanguard will report beneficial ownership separately (on a disaggregated basis).
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by these subsidiaries and/or business divisions.
• The CUSIP number for Coherus Oncology Inc. Common Stock is 19249H103.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral for Coherus Oncology Inc. as it primarily reflects an internal reporting change by The Vanguard Group rather than a change in investment thesis or a significant divestment of underlying shares from Vanguard's managed funds.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding Coherus Oncology Inc.'s future performance or operations.

Management Comments

• Ashley Grim, Head of Global Fund Administration for The Vanguard Group, certified that the information set forth in the statement is true, complete, and correct.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are used by passive investors, such as mutual funds and institutional asset managers like The Vanguard Group, to report beneficial ownership of 5% or more of a company's stock. An amendment reporting 0% ownership due to an internal realignment, rather than a divestment, is a technical reporting change. It indicates a shift in how Vanguard's various entities report their holdings, not necessarily a change in the overall investment position of Vanguard-managed funds in Coherus Oncology Inc. This type of filing is common for large asset managers undergoing internal structural adjustments.

Stakeholder Impact

• Shareholders of Coherus Oncology Inc. may note the change in reporting structure by a major institutional investor, but this filing does not indicate a change in the underlying investment by Vanguard's funds.

Key Dates

Keywords

Coherus Oncology Inc., The Vanguard Group, Schedule 13G, Beneficial Ownership, SEC Filing, Institutional Investor, Common Stock, Corporate Realignment